$-0.01 EPS Expected for SANUWAVE Health, Inc. (SNWV); Cellectis SA Ads (CLLS) Shorts Down By 24.25%

October 30, 2017 - By Darrin Black

Analysts expect SANUWAVE Health, Inc. (OTCMKTS:SNWV) to report $-0.01 EPS on November, 14.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.01 EPS. After having $-0.01 EPS previously, SANUWAVE Health, Inc.’s analysts see 0.00% EPS growth. About 130,823 shares traded. SANUWAVE Health, Inc. (OTCMKTS:SNWV) has 0.00% since October 30, 2016 and is . It has underperformed by 16.70% the S&P500.

Cellectis SA Ads (NASDAQ:CLLS) had a decrease of 24.25% in short interest. CLLS’s SI was 515,300 shares in October as released by FINRA. Its down 24.25% from 680,300 shares previously. With 88,300 avg volume, 6 days are for Cellectis SA Ads (NASDAQ:CLLS)’s short sellers to cover CLLS’s short positions. The SI to Cellectis SA Ads’s float is 2.13%. About 150,012 shares traded or 5.10% up from the average. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 17.09% since October 30, 2016 and is downtrending. It has underperformed by 33.79% the S&P500.

SANUWAVE Health, Inc. is an acoustic pressure shock wave technology firm using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The company has market cap of $18.08 million. The Firm is focused on regenerative medicine utilizing noninvasive , acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. It currently has negative earnings. The Company’s lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has market cap of $1.20 billion. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Among 7 analysts covering Cellectis (NASDAQ:CLLS), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Cellectis had 13 analyst reports since April 5, 2016 according to SRatingsIntel. The stock of Cellectis SA (ADR) (NASDAQ:CLLS) earned “Buy” rating by Jefferies on Monday, September 25. Jefferies maintained Cellectis SA (ADR) (NASDAQ:CLLS) rating on Thursday, August 24. Jefferies has “Buy” rating and $47.0 target. The firm has “Hold” rating by SunTrust given on Friday, October 6. Jefferies maintained Cellectis SA (ADR) (NASDAQ:CLLS) rating on Friday, October 27. Jefferies has “Buy” rating and $47.0 target. The rating was maintained by Oppenheimer on Wednesday, August 16 with “Buy”. The rating was initiated by Ladenburg Thalmann with “Buy” on Tuesday, April 5. The rating was maintained by Oppenheimer on Friday, June 2 with “Buy”. Nomura maintained Cellectis SA (ADR) (NASDAQ:CLLS) on Wednesday, September 6 with “Buy” rating. The company was downgraded on Wednesday, September 6 by SunTrust. On Tuesday, February 28 the stock rating was initiated by Wells Fargo with “Outperform”.